{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:37:37Z","timestamp":1785469057545,"version":"3.56.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.euo.2023.02.008","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T16:26:31Z","timestamp":1678379191000},"page":"251-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"6","author":[{"given":"Elisabeth","family":"Grobet-Jeandin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Lenfant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Giannarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Alcaraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Albersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Breda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2023.02.008_b0005","unstructured":"IARC, Cancer Today. Estimated number of new cases in 2020, worldwide, both sexes, all ages. 2021. https:\/\/gco.iarc.fr\/today\/online-analysis-table."},{"key":"10.1016\/j.euo.2023.02.008_b0010","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.02.008_b0015","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrurol.2017.82","article-title":"Landmarks in the treatment of muscle-invasive bladder cancer","volume":"14","author":"Lobo","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2023.02.008_b0020","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/JU.0000000000002242","article-title":"Management trends and outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder: evolution of the University of Southern California experience over 3,347 cases","volume":"207","author":"Mitra","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2023.02.008_b0025","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.02.008_b0030","doi-asserted-by":"crossref","unstructured":"International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011;29:2171\u20137.","DOI":"10.1200\/JCO.2010.32.3139"},{"key":"10.1016\/j.euo.2023.02.008_b0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","article-title":"A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2023.02.008_b0040","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2023.02.008_b0045","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.02.008_b0050","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2023.02.008_b0055","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.02.008_b0060","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.urology.2010.01.087","article-title":"Body image and bladder cancer specific quality of life in patients with ileal conduit and neobladder urinary diversions","volume":"76","author":"Hedgepeth","year":"2010","journal-title":"Urology"},{"issue":"Suppl 2","key":"10.1016\/j.euo.2023.02.008_b0065","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1442-2042.1995.tb00482.x","article-title":"Neoadjuvant and adjuvant chemotherapy in advanced disease\u2013what are the effects on survival and prognosis?","volume":"2","author":"Sternberg","year":"1995","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2023.02.008_b0070","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2023.02.008_b0075","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2017.08.016","article-title":"Key steps in conducting systematic reviews for underpinning clinical practice guidelines: methodology of the European Association of Urology","volume":"73","author":"Knoll","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.02.008_b0080","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0022-5347(17)35024-3","article-title":"Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: a 5-year followup","volume":"151","author":"Srougi","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2023.02.008_b0085","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s002800050247","article-title":"Phase II study of a new combined primary chemotherapy regimen, intravenous methotrexate and vincristine and intraarterial adriamycin and cisplatin, for locally advanced urinary bladder cancer: preliminary results","volume":"35","author":"Kuroiwa","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.euo.2023.02.008_b0090","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/S0022-5347(01)66041-5","article-title":"Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors","volume":"155","author":"Angulo","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2023.02.008_b0095","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1200\/JCO.1998.16.4.1298","article-title":"Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome","volume":"16","author":"Herr","year":"1998","journal-title":"J Clin"},{"key":"10.1016\/j.euo.2023.02.008_b0100","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1023\/A:1008350518083","article-title":"Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder","volume":"10","author":"Sternberg","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2023.02.008_b0105","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/cncr.11232","article-title":"Can patient selection for bladder preservation be based on response to chemotherapy?","volume":"97","author":"Sternberg","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2023.02.008_b0110","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.eururo.2007.12.031","article-title":"Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"54","author":"Herr","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.02.008_b0115","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.eururo.2008.08.027","article-title":"Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy","volume":"55","author":"Solsona","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.02.008_b0120","doi-asserted-by":"crossref","unstructured":"deVere White RW, Lara PN, Goldman B, et al. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol 2009;181:2476\u201380; discussion 2480\u20131.","DOI":"10.1016\/j.juro.2009.01.115"},{"key":"10.1016\/j.euo.2023.02.008_b0125","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000316076","article-title":"Bladder preservation strategy based on combined therapy in patients with muscle-invasive bladder cancer: management and results at long-term follow-up","volume":"85","author":"Villavicencio","year":"2010","journal-title":"Urol Int"},{"key":"10.1016\/j.euo.2023.02.008_b0130","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.juro.2014.03.078","article-title":"The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder","volume":"192","author":"Meyer","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2023.02.008_b0135","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1159\/000369301","article-title":"Intra-arterial chemotherapy for muscle-invasive bladder cancer following transurethral resection","volume":"94","author":"Liang","year":"2015","journal-title":"Urol Int"},{"key":"10.1016\/j.euo.2023.02.008_b0140","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.juro.2018.05.078","article-title":"Conservative management following complete clinical response to neoadjuvant chemotherapy of muscle invasive bladder cancer: contemporary outcomes of a multi-institutional cohort study","volume":"200","author":"Mazza","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2023.02.008_b0145","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.urology.2017.09.003","article-title":"Outcomes following clinical complete response to neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder in patients refusing radical cystectomy","volume":"111","author":"Robins","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.euo.2023.02.008_b0150","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.annonc.2020.09.011","article-title":"Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study","volume":"31","author":"Bandini","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2023.02.008_b0155","doi-asserted-by":"crossref","first-page":"132.e1","DOI":"10.1016\/j.urolonc.2020.07.016","article-title":"Impact of noninvasive down-staging after transurethral resection of bladder tumor plus systemic chemotherapy on bladder-sparing strategy in patients with muscle-invasive bladder cancer","volume":"39","author":"Onishi","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2023.02.008_b0160","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0360-3016(91)90050-E","article-title":"Curative radiotherapy following chemotherapy for invasive bladder carcinoma (a preliminary report)","volume":"20","author":"Farah","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2023.02.008_b0165","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0360-3016(98)00013-3","article-title":"Invasive bladder cancer: our experience with bladder sparing approach","volume":"41","author":"Cervek","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2023.02.008_b0170","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0022-5347(01)63549-3","article-title":"The fate of patients with locally advanced bladder cancer treated conservatively with neoadjuvant chemotherapy, extensive transurethral resection and radiotherapy: 10-year experience","volume":"159","author":"Serretta","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2023.02.008_b0175","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijrobp.2008.11.030","article-title":"Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer","volume":"75","author":"Lin","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2023.02.008_b0180","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/bjc.2015.109","article-title":"Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder","volume":"112","author":"Hafeez","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2023.02.008_b0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-0041-1723076","article-title":"Bladder preservation with neoadjuvant chemotherapy followed by concurrent chemoradiation for the treatment of muscle-invasive carcinoma of the bladder: a single-center experience","volume":"9","author":"Agrawal","year":"2020","journal-title":"South Asian J Cancer"},{"key":"10.1016\/j.euo.2023.02.008_b0190","doi-asserted-by":"crossref","first-page":"684879","DOI":"10.3389\/fimmu.2021.684879","article-title":"A muscle-invasive bladder cancer patient with high tumor mutational burden and RB1 mutation achieved bladder preservation following chemotherapy combined with immunotherapy: a case report","volume":"12","author":"Cao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.euo.2023.02.008_b0195","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.21.01003","article-title":"Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer","volume":"39","author":"Rose","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.02.008_b0200","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","article-title":"Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer","volume":"61","author":"Rosenblatt","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.02.008_b0205","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/JU.0000000000001602","article-title":"Cystoscopy and systematic bladder tissue sampling in predicting pT0 bladder cancer: a prospective trial","volume":"205","author":"Zibelman","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2023.02.008_b0210","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2020.07.016","article-title":"Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"79","author":"Becker","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.02.008_b0215","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","article-title":"Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting and Data System)","volume":"74","author":"Panebianco","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.02.008_b0220","doi-asserted-by":"crossref","first-page":"627.e13","DOI":"10.1016\/j.crad.2021.03.001","article-title":"Radiomics-based model for predicting pathological complete response to neoadjuvant chemotherapy in muscle-invasive bladder cancer","volume":"76","author":"Choi","year":"2021","journal-title":"Clin Radiol"},{"key":"10.1016\/j.euo.2023.02.008_b0225","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1017\/S0266462310001364","article-title":"Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis","volume":"27","author":"Mowatt","year":"2011","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.euo.2023.02.008_b0230","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00345-015-1568-6","article-title":"En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor","volume":"33","author":"Kramer","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2023.02.008_b0235","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.urology.2012.07.045","article-title":"Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy","volume":"80","author":"Zapatero","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.euo.2023.02.008_b0240","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.euo.2020.02.003","article-title":"Defects in DNA repair genes confer improved long-term survival after cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"3","author":"Miron","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2023.02.008_b0245","first-page":"340","article-title":"Bladder-sparing treatment of invasive bladder cancer","volume":"7","author":"Rivera","year":"2000","journal-title":"Cancer Control J Moffitt Cancer Cent"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123000408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123000408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:48:45Z","timestamp":1762876125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931123000408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2588931123000408"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2023.02.008","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2023.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}